Opposing effects of ketamine and acetyl l-carnitine on the serotonergic system of zebrafish. (21st October 2015)

• Record Type: Journal Article
• Authors: Robinson, Bonnie L.; Dumas, Melanie; Paule, Merle G.; Ali, Syed F.; Kanungo, Jyotshna
• Is Part Of: Neuroscience letters. Volume 607(2015)
• Page Start: 17
• Page End: 22
• Publication Date: 2015-10-21
• Subjects: Ketamine -- Zebrafish -- Acetyl l-carnitine -- Serotonin -- Metabolism -- HPLC/EC; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2015.09.006
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Low doses of ketamine do not alter 5-HT and 5-HIAA levels in zebrafish embryos. Anesthetic dose of ketamine reduces 5-HT levels and abolishes its metabolism to 5-HIAA. ALCAR reverses the effects of ketamine on the 5-HT level and metabolism. Anesthetic dose of ketamine reduces serotonin-positive cells in the brain. Ketamine and ALCAR are being tested as anti-depressants, these results indicate their possible modes of action on the 5-HT system. Abstract: Ketamine, a pediatric anesthetic, is a noncompetitive N -methyl-d -aspartic acid (NMDA) receptor antagonist. Studies show that ketamine is neurotoxic in developing mammals and zebrafish. In both mammals and zebrafish, acetyll -carnitine (ALCAR) has been shown to be protective against ketamine toxicity. Ketamine is known to modulate the serotonergic system in mammals. Here, we measured the levels of serotonin (5-HT) and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in the embryos exposed to ketamine in the presence and absence of ALCAR. Ketamine, at lower doses, did not produce significant changes in the 5-HT or 5-HIAA levels in 3 dpf (day post-fertilization) embryos. However, 2 mM ketamine (internal embryo exposure levels comparable to human anesthetic plasma concentration) significantly reduced 5-HT level, and 5-HIAA was not detectable indicating that 5-HT metabolism was abolished. In the presence or absence of 2 mM ketamine, ALCAR by itself did not significantly alter 5-HT or 5-HIAA levels compared to the control. Ratios of metabolite/5-HT indicated that 2 mM ketamine inhibited 5-HT metabolism to 5-HIAA whereas lower doses (0.1–0.3 mM) of ketamine did not have any effect. ALCAR reversed the effects of 2 mM ketamine not only by restoring 5-HT and 5-HIAA levels but also 5-HT turnover rate to control levels. Whole mount immunohistochemical studies showed that 2 mM ketamine reduced the serotonergic area in the brain whereas ALCAR expanded it with increased axonal sprouting and branching. These results indicate that ketamine and ALCAR have opposing effects on the zebrafish serotonergic system.